Skip To Main Content
Christophe Roul on Muck Rack

Christophe Roul

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Christophe Roul’s profile

Articles by Christophe Roul

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

|
By Arthur Bobin, Lisa Ann Durocher, Cyrille Touzeau, Aurore Perrot, Jean-Sébastien Bladé, Thomas Chalopin, Julie Gay, Mourad Tiab, Margaret Macro, Titouan Cazaubiel, Alberto Santagostino, Reza Tabrizi, Olivier Fitoussi, Rick Zhang, Murielle Roussel, Lionel Karlin, Mohamad Mohty Verified, Philippe Moreau, Anaïs Schavgoulidze, Jill Corre, Thierry Facon, Cyrille Hulin, Salomon Manier, Stéphanie Ragot, Xavier Leleu, Nicolas Branche, Mamoun Dib, Lydia Montes, Frédérique Orisini Piocelle, Adrienne De Thomas De Labarthe, Marlène Ochmann, Christophe Roul, Muriel Newinger-Porte, Mony Morisse Chenda, Douaa Dhahri
| Nature Verified
Abstract Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate treatment administration. ISASOCUT is a prospective, multicenter, phase 2 study evaluating the efficacy and tolerability of Isa SC-VRd administered via OBI.
Open in Who Shared Issue with article?
Show More